NEW YORK (GenomeWeb) – Proteomics firm Caprion Biosciences said today that it has been acquired by London-based healthcare investment firm GHO Capital.
GHO purchased the company for an undisclosed amount from Chicago Growth Partners, Caprion's majority shareholder since 2012. Caprion said that it will continue to operate out of its current Montreal headquarters under the leadership of its existing management team.
Caprion provides immunology and proteomics research services to pharmaceutical and biotechnology companies. The firm is also developing its own in-house diagnostics, with its first planned offering a proteomic test for detecting the onset of diabetes and managing the disease.
In a statement, Caprion CEO Martin LeBlanc called the GHO deal a "very successful outcome" for the company's investors and "tangible evidence of the strong business performance and growth that Caprion has achieved during our four-year partnership with Chicago Growth Partners."